Nuvectis Pharma, Inc.

NASDAQ:NVCT

Biotechnology

Healthcare
$20.29 +3.06%

+$0.39 today

Market cap
$697.75M
Beta
-0.07
P/E (TTM)
-11.2
EPS (TTM)
-$1.16
52W Low $5.55High $13.51

Volume 0.19M

Average 0.08M

NVCT Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Nuvectis Pharma, Inc.NASDAQ: NVCT

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) remains negative

Q1 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.

Context

  • Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue (non-current) increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue (Non-current) vs competitors

How NVCT compares with its peers on the latest reported figures

  • NVCT's Mar 2026 deferred revenue (non-current) of $0 is the 3rd highest of the 11 companies compared; the peer median is $0.
  • Deferred revenue (non-current) amounts to 0.0% of total assets for NVCT, versus a peer median of 0.0%.
NVCT Competitors Peer median
Deferred Revenue (Non-current) for NVCT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NUVBNuvation Bio Inc.Jun 2026$151.12M +1113.0%—20.3%
JANXJanux Therapeutics, Inc.Mar 2026$8.68M ——0.8%
NVCTNuvectis Pharma, Inc.Mar 2026$0 ——0.0%
VSTMVerastem, Inc.Mar 2026$0 ——0.0%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
IMMXImmix Biopharma, Inc.Mar 2026$0 ——0.0%
IMRXImmuneering CorporationMar 2026$0 ——0.0%
MGNXMacroGenics, Inc.Mar 2026$0 -100.0%-2.3%0.0%
CMPXCompass Therapeutics, Inc.Mar 2026$0 ——0.0%
MREOMereo BioPharma Group plcMar 2026$0 ——0.0%
Peer median (excluding NVCT) $0+506.5%-2.3%0.0%

Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents5.74M19.99M19.13M18.53M31.63M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets91K412K59K74K75K
Total Current Assets5.83M20.41M19.19M18.61M31.71M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets824K0000
Total Non-current Assets824K0000
Total Assets6.66M20.41M19.19M18.61M31.71M
Account Payables1.06M2.91M2.77M2.5M6.27M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities142K2.38M3.8M5.56M6.91M
Total Current Liabilities2.42M6.19M6.98M8.89M13.3M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities15.25M0000
Total Non-current Liabilities15.25M0000
Total Liabilities17.67M6.19M6.98M8.89M13.3M
Common Stock00000
Retained Earnings(12.9M)(31.99M)(54.25M)(73.25M)(99.69M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(11.01M)14.22M12.2M9.71M18.41M
Total Debt00000
Net Debt(5.74M)(19.99M)(19.13M)(18.53M)(31.63M)

Nuvectis Pharma, Inc.

NASDAQ:NVCT

Intrinsic Alpha fair value

Locked

Current Price

$20.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.